These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2578 related articles for article (PubMed ID: 31703637)

  • 21. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
    Kuon J; Hommertgen A; Krisam J; Lasitschka F; Stenzinger A; Blasi M; Bozorgmehr F; Maenz M; Kieser M; Schneider M; Thomas M
    Trials; 2020 Apr; 21(1):352. PubMed ID: 32321565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
    Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
    Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
    Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
    Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
    Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
    Tartarone A; Roviello G; Lerose R; Roudi R; Aieta M; Zoppoli P
    Future Oncol; 2019 Jul; 15(20):2423-2433. PubMed ID: 31237152
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
    Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.
    Ratnayake G; Shanker M; Roberts K; Mason R; Hughes BGM; Lwin Z; Jain V; O'Byrne K; Lehman M; Chua B
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):56-62. PubMed ID: 31721446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
    Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
    Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 129.